Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's Endeavor DES (drug-eluting stent) gains market approval in China:

This article was originally published in Clinica

Executive Summary

Medtronic has received regulatory approval for its Endeavor drug-eluting stent (DES) from the government of the People's Republic of China. The zotarolimus (ABT-578) delivering stent is built from a cobalt alloy, based on the same platform as the Driver, its bare metal stent product. It is coated with phosphorylcholine, a polymer which mimics the outside surface of a red blood cell, in order improve healing response. The DES market in China currently stands at around $100m, and some 70,000 implants are performed every year, said the Santa Rosa, California-based firm. The firm received CE-marking for the stent in July 2005, and hopes for PMA approval in the US during 2007.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel